Sugi Predict

Sugi Predict / Compounds / SCHEMBL461050

SCHEMBL461050

SCHEMBL461050

O=C(O)c1cnn2ccc(Cl)nc12

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 5/20 0.44
▸ TGFBR1 P36897 3/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ EPHB3 P54753 4/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ PIK3CA P42336 3/20 0.38
▸ RIPK2 O43353 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ DHODH Q02127 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401639 0.88 FLT3 (0.41) FLT3EPHB3PIK3CARIPK2LCK
SCHEMBL448581 0.87 TGFBR1 (0.46) FLT3TGFBR1JAK2JAK1TYK2
SCHEMBL10246668 0.87 FLT3 (0.43) FLT3EPHB3PIK3CAJAK2TYK2
SCHEMBL30993352 0.83 TGFBR1 (0.49) TGFBR1EPHB3KDM4EJAK2JAK1
SCHEMBL10190991 0.83 PDE4B (0.47) FLT3L3MBTL1EPHB3KDM4ETYK2
SCHEMBL461457 0.81 TGFBR1 (0.42) TGFBR1L3MBTL1KDM4ETYK2SMN1; SMN2
SCHEMBL402500 0.79 TGFBR1 (0.50) TGFBR1KDM4ESMN1; SMN2
SCHEMBL402097 0.79 JAK2 (0.48) JAK2IRAK4
SCHEMBL30267077 0.79 FLT3 (0.38) FLT3TGFBR1EPHB3PIK3CAJAK2
SCHEMBL405711 0.79 JAK2 (0.48) TGFBR1JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250375451-A1 CHIRAL DIARYL MACROCYCLES AND USES THEREOF TURNING POINT THERAPEUTICS INC (US) 2025-12-11 — — US disclosed
US-20250223298-A1 DIARYL MACROCYCLE POLYMORPH Turning Point Therapeutics, Inc. 2025-07-10 — — US disclosed
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2025-07-03 — — US disclosed
US-12310968-B2 Chiral diaryl macrocycles and uses thereof Turning Point Therapeutics, Inc. (US) 2025-05-27 — — US disclosed
EP-4493562-A1 TYK2 INHIBITORS AND USES THEREOF Alumis Inc. (US) 2025-01-22 — — EP disclosed
US-12187739-B2 Diaryl macrocycle polymorph Turning Point Therapeutics, Inc. (US) 2025-01-07 — — US disclosed
CN-113527298-B Macrocyclic lactam derivatives, preparation method and application thereof 浙江海正药业股份有限公司 2025-01-03 — — CN disclosed
CN-113354653-B Diaryl macrocyclic polymorphs and processes for their preparation 特普医药公司 2024-12-31 — — CN disclosed
WO-2024262911-A1 NOVEL PYRAZOLO PYRIMIDINE-BASED COMPOUND AND USE THEREOF 주식회사 에이조스바이오 2024-12-26 — — WO disclosed
EP-4480543-A2 CHIRAL DIARYL MACROCYCLE AND USE THEREOF IN THE TREATMENT OF CANCER Turning Point Therapeutics, Inc. (US) 2024-12-25 — — EP disclosed
EP-2962566-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS Genentech, Inc. (US) 2016-01-06 — — EP disclosed
US-20150336962-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2015-11-26 — — US disclosed
WO-2015177326-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-11-26 — — WO disclosed
WO-2015112806-A2 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP THERAPEUTICS, INC. (US) 2015-07-30 — — WO disclosed
EP-2348860-B1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH INC (US) 2015-05-27 — — EP disclosed
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2014-04-17 — — US disclosed
US-8637526-B2 Pyrazolopyrimidine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2014-01-28 — — US disclosed
EP-2451812-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS Array Biopharma, Inc. (US) 2012-05-16 — — EP disclosed
WO-2012034095-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-03-15 — — WO disclosed
WO-2010051549-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375451-A1 CHIRAL DIARYL MACROCYCLES AND USES THEREOF PKD1, PKD2, CYP7B1 FLT3 725/4885TGFBR1 3880/4885L3MBTL1 917/4885
US-12310968-B2 Chiral diaryl macrocycles and uses thereof PKD1, DHCR7, PKD2 FLT3 744/4885TGFBR1 3342/4885L3MBTL1 546/4885
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 FLT3 169/4885TGFBR1 2189/4885L3MBTL1 1227/4885
US-20150336962-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, FLT3 FLT3 3/4885TGFBR1 3820/4885L3MBTL1 4715/4885
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 FLT3 16/4885TGFBR1 1184/4885L3MBTL1 1966/4885
US-12187739-B2 Diaryl macrocycle polymorph PKD1, CYP7B1, BRCA1 FLT3 840/4885TGFBR1 4006/4885L3MBTL1 1258/4885
US-20250223298-A1 DIARYL MACROCYCLE POLYMORPH PKD1, CYP7B1, BRCA1 FLT3 840/4885TGFBR1 4006/4885L3MBTL1 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.